Conversely, the favorable role of HLA-A*24:02 expression on PCa clinical outcomes might be interpreted by the increased immunogenicity of HLA-A24+ PCa cells, leading to long periods of tumor control under immunosurveillance during “equilibrium”. The gene discussed is HLA-A; the disease is neoplasm.